natgillin/translations-raw huggingface dataset:
A pharmaceutical tablet especially in accordance with the preceding items having (a) a cracking force of at least 110 N, preferably 120 N, more preferably 130 N, and even more preferably 140 N, when subjected to an indentation test; (b) a penetration depth to crack distance of at least 1.0 mm, preferably 1.2 mm, more preferably 1.4 mm, and even more preferably 1.6 mm, when subjected to an indentation test; and (c) capable of resisting a work of at least 0.06 J without cracking. 
Farmaceutska tableta prema prethodnim zahtjevima naznačena time da ima (a) silu loma od najmanje 110 N, poželjno 120 N, poželjnije 130 N, te najpoželjnije 140 N, kada je podvrgnuta indentacijskom testu; (b) dubinu prodiranja s razmakom pukotine od najmanje 1.0 mm, poželjno 1.2 mm, poželjnije 1.4 mm, te najpoželjnije 1.6 mm, kada je podvrgnuta indentacijskom testu; te (c) da se može oduprijeti radu od najmanje 0.06 J bez loma. S Temperatura
The medium of claim 16, wherein the coding tools include spectral extension processing and the decoding of each respective audio block further comprises: determining whether the decoding process should use spectral extension processing to decode any of the encoded audio data; and if spectral extension processing should be used, synthesizing one or more spectral components from the inverse secondary transform coefficients to obtain primary transform coefficients with an extended bandwidth. 
Postupak prema zahtjevu 2, naznačen time da alati za kodiranje sadrže obradu spektralnog proširenja i dekodiranje svakog odgovarajućeg audio bloka dodatno sadrži: utvrđivanje da li proces dekodiranja treba koristiti spektralnu proširenu obradu za dekodiranje bilo kojeg od kodiranih audio podataka; te ako se treba koristiti spektralna proširena obrada, sintetiziranje jedne ili više spektralnih komponenti iz inverznih sekundarnih transformacijskih koeficijenata da se dobiju primarni transformacijski koeficijenti sa proširenom propusnosti.
• determination ofHPV (human papilloma virus DNA) in cervical cells 
određivanje HPV (DNA humanog papiloma virusa) u stanicama grlića maternice,
from Compound B of the formula comprising oxidation of Compound B in a continuous reactor through which a solution of Compound B and hydrogen peroxide and an acid, while being cooled, are contacted as they continuously flow through the reactor. 
HR P2013099 T1 iz Spoja B formule koji obuhvaća oksidaciju Spoja B u kontinuiranom reaktoru kroz koji u doticaj dolaze otopina Spoja B i vodikov peroksid 1 kiselina, dok se istodobno hlade, i dok kontinuirano prolaze kroz reaktor.
The panel according to any claims 1 to 9 characterized in that in modular sandwich element (1) there are integrated sealing elements and there is only attaching of said modular sandwich panel (1) performed on the building or securing of attaching position from water ingression and for aesthetical reasons. 
Panel prema bilo kom od zahtjeva 1 do 9, naznačen time što su u modularni sendvič element (1) integrirani brtveni elementi i što se na objektu vrši samo pričvršćivanje spomenutog modularnog sendvič panela (1) 1 zatvaranje, odnosno zaštita mjesta vijaka protiv prodiranja vode i iz estetskih razloga.
From day 20 (D20, D23, D26,... up to D62), the RB1750 cm2 were diluted in a repetitive manner every 3 days, respecting a dilution ratio of 1/4. 
Od 20. dana nadalje (D20, D23, D26,... sve do D62), RB 1750 cm? ponavljano su razrjeđivane svaka 3 dana, poštujući omjer razrjeđenja od 1/4.
The kit of claim 8, further comprising one or more doses of a chemotherapeutic agent. 
Oprema prema zahtjevu 5, nadalje sadrži jednu ili više doza kemoterapijskog agenta.
According to a particular embodiment of the invention, the end 31 of the rod 3 is connected to the body 2 with which it forms a single body in plastic material that is obtained by extrusion, and the removable connection is achieved by means of a pre-breaking cut. 
Alat u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time, da je kraj (31) šipke (3) povezan s tijelom (2) s kojim tvori jedinstveno tijelo od plastičnog materijala koje je dobiveno ekstruzijom, a odvojiva veza ostvaruje se pomoću reza na unaprijed urezanom položaju.
The methodology of claim 7, wherein the DNA marker is amplified using the primers set forth in SEQ ID NOs:14 and 15 and the amplicon is probed with a fluorophore-labeled probe with a sequence set forth in SEQ ID NO:16. 
Metodologija prema patentnom zahtjevu 7, naznačena time da je DNA marker umnožen upotrebom primera navedenih pod SEQ ID NO:14 i 15 dok je produkt amplifikacije obilježen sondom sa fluoroforo – sondom sa sekvencom SEQ ID NO:16.
obtaining quantized transformation coefficients of a transformation unit in the coding unit by performing entropy decoding on the bitstream encoded based on the coding unit; 
raščlanjivanje, iz toka bitova, kvantiziranih koeficijenata transformacije barem jedne transformacijske jedinice u jedinici za kodiranje;
The method of claim 14 wherein said molecule retains at least 50% of native FVIII I I activity, preferably at least 80% of native FVIII activity. 
Molekula prema zahtjevu 6, pri čemu navedena molekula zadržava barem 80% prirodne biološke aktivnosti FVIII.
515 516 or its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures thereof, or at least one pharmaceutically acceptable salt thereof. 
ee, ili njihova racemična smjesa, njihovi enantiomeri, dijastereomeri, tautomeri, ili njihove mješavine, ili najmanje jedna njihova farmaceutski prihvatljiva sol.
Another embodiment of the present invention relates to a pharmaceutical composition comprising as active ingredient at least one of the derivatives of dianhydrohexite mononitrate according to formula (I), a tautomer, a pharmaceutically acceptable salt, a prodrug or a solvate thereof. 
Druga izvedba predloženog izuma odnosi se na farmaceutski sastav koji kao aktivan sastojak sadrži najmanje jedan derivat dianhidroheksit mononitrata prema formuli (I), njegov tautomer, farmaceutski prihvatljivu sol ili njegov solvat.
A vectored vaccine comprising a non-replicating or replication impaired poxvirus vector expressing the translation product of the nucleotide sequence of SEQ ID NO: 4, and additionally including a PK C-terminus tag and a TPA leader sequence, wherein said vectored vaccine is capable of inducing an immune response which persists for at least one year. 
Vektorsko cjepivo koje sadrži poxvirus kao ne-replicirajući vektor, ili vektor s poremećajem replikacije, koji cksprimira produkt translacije nuklcotidne sekvence SEQ ID NO: 4, i dodatno sadrži s PK označen C-kraj, TPA vodeću sekvencu, pri čemu to vektorsko cjepivo može inducirati imuni odgovor koji traje najmanje 1 godinu.
In addition, formulas containing this material are not slippery on the hand, allowing a surer hand grip for the user. Unlike many other polyamide resins, this material has a softening point below 80 degrees Celsius which is an added convenience in formulating because the addition of the waterproofing agent allows the formulation to be formulated at lower temperatures and thus is more convenient. 
Dodatno, formule koje sadržavaju ovaj materijal nisu klizave na ruci, što omogućuje sigurnije držanje ruke za korisnika, Za razliku od mnogih drugih poliamidnih smola, ovaj materijal ima točku mekšanja ispod 80 stupnjeva Celziusa, što je dodatna pogodnost kod formuliranja, zato što dodavanje sredstva za vodootpornost omogućuje formuliranje pripravka na nižim temperaturama i prema tome je prikladnije.
a light chain variable region, wherein the CDRL1 comprises the amino acid sequence of SEQ ID NO:7, the CDRL2 comprises the amino acid sequence of SEQ ID NO:17, the CDRL3 comprises the amino acid sequence of SEQ ID NO:29, and a heavy chain variable region wherein the CDRH1 comprises the amino acid sequence of SEQ ID NO:45, the CDRH2 comprises the amino acid sequence of SEQ ID NO:77, and the CDRH3 comprises the amino acid sequence of SEQ ID NO:87; 
varijabilnu regiju lakog lanca, pri čemu CDRL1 sadrži sekvencu aminokiselina SEQ ID NO:7, CDRL2 sadrži sekvencu aminokiselina SEQ ID NO:21, CDRL3 sadrži sekvencu aminokiselina SEQ ID NO:29, i varijabilnu regiju teškog lanca pri čemu CDRH1 sadrži sekvencu aminokiselina SEQ ID NO:41, CDRH2 sadrži sekvencu aminokiselina SEQ ID NO:75, i CDRH3 sadrži sekvencu aminokiselina SEQ ID NO:87, pri čemu se navedeno protutijelo veže za ljudski IL-6 ili njegov fragment sa afinitetom od 0,1-9,9 x 10-14 M kao što se određuje Kinexa® postupkom.
The method according to claim 1, wherein said model is an electrical equivalent circuit diagram, a state-space model or dynamic simulation model. 
Postupak sukladno bilo kojem od prethodnih zahtjeva, pri čemu je navedeni model (30) električni ekvivalentni dijagram kruga, razvojno prostorni model ili dinamički simulacijski model.
treating the thus-washed bone powder overnight with 0.5N HCl while being shaken at 10 to 100 rpm; 
obrade tako ispranog koštanog tkiva u prahu preko noći sa 0.5N HCl uz protresanje kod 10 do 100 okr/min;
obtaining a context set index used in entropy decoding of a second critical value flag indicating whether the significant transformation coefficient has a value greater than a second critical value based on the context set index used in entropy decoding of the first critical value flag, wherein, when a color component of the transformation unit is a luminance component, the context set index is obtained based on location information of the current subset indicating at which location the current subset is located in the transformation unit, wherein, when the color component of the transformation unit is a chrominance component, the context set index is obtained independently of the location information of the current subset. 
pri čemu, kada je komponenta boje jedinice za transformaciju komponenta osvijetljenosti, indeks skupa konteksta se pribavlja na osnovu informacija o lokaciji trenutnog podskupa koji označava na kojoj lokaciji se trenutni podskup nalazi u jedinici za transformaciju, pri čemu. kada je komponenta boje jedinice za transformaciju komponenta osvijetljenosti, indeks skupa konteksta se pribavlja neovisno od informacija o lokaciji trenutnog podskupa.
The apparatus according to one of Claims 1 to 13, characterized in that the first insulator comprises a filtration facility. 
Uređaj prema jednom od Zahtjeva 1 do 13, naznačen time da prvi izolator sadržava jedinicu za filtriranje.
A control unit (1) according to claim 7, comprising at least a first and a second capacitive element, which are associated with the contact sensor device and with the position sensor device respectively, the second capacitive element being arranged perimetrically to the first capacitive element. 
Upravljačka jedinica (1) u skladu s patentnim zahtjevom 7, naznačena time, da sadržava barem prvi i drugi kapacitivni element koji su povezani sa senzorskim uređajem kontakta i uređajem senzora položaja, pri čemu je drugi kapacitivni element postavljen na vanjskom rubu u odnosu na prvi kapacitivni element.
A compound according to any one of claims 1 to 8 wherein each aryl independently may be phenyl optionally substituted with C1-6alkyl, amino, mono- or diC1-6alkyl-amino, C1-6alkyloxy, aminosulfonyl, Het, the latter more in particular being thiadiazolyl 
Spoj prema bilo kojem od zahtjeva 1 do 8 naznačen time da svaki aril nezavisno može biti fenil po izboru supstituiran sa C1-6alkil, amino, mono- ili diC1-6alkil-amino, C1-6alkiloksi, aminosulfonil, Het, potonji je posebice tiadiazolil.
The compound or pharmaceutically acceptable salt for use according to claim 9, wherein the disease is heart failure. 
Spoj ili farmaceutski prihvatljiva sol za uporabu u skladu sa zahtjevom 9, pri čemu je bolest zatajenje srca.
The composition or aerosol of claim 15, wherein the other antimicrobial is an aminoglycoside, polymyxin, a monobactam, a macrolide, or ketolide, a glycopeptide, or a fluoroquinolone. 
16. Smjesa ili aerosol iz patentnog zahtjeva 15, pri čemu drugi antimikrobni agens je aminoglikozid, polimiksin, monobaktam, makrolid, ili ketolid, glikopeptid, ili fluorokinolin.
A compound of formula ((S,S)-SDG-1) or a compound of formula (R,R)-SDG-2 prepared by a process comprising: 
PATENTNI ZAHTJEVI 1. > Postupak za pripremu spoja formule (($,S)-SDG-1) ili spoja formule (R,R)-SDG-2 pe
A co-suspension according to any preceding claim wherein the pharmaceutically acceptable salt of glycopyrrolate is selected from fluoride, chloride, bromide, iodide, nitrate, sulfate, phosphate, formate, acetate, trifluoroacetate, propionate, butyrate, lactate, citrate, tartrate, malate, maleate, succinate, benzoate, p-chlorobenzoate, diphenyl-acetate or triphenylacetate, o-hydroxybenzoate, p-hydroxybenzoate, 1 -hydroxynaphthalene-2- carboxylate, 3-hydroxynaphthalene-2-carboxylate, methanesulfonate and benzenesulfonate. 
Ko-suspenzija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se farmaceutski prihvatljiva sol glikopirolata bira između fluorida, klorida, bromida, jodida, nitrata, sulfata, fosfata, formijata, acetata, trifluoracetata, propionata, butirat, laktata, citrata, tartarata, malata, maleata, sukcinata, benzoata, p- klorbenzoata, difenilacetata ili trifemilacetata, o-hidroksibenzoata, p-hidroksibenzoat, 1-hidroksinaftalen-2-karboksilata, 3-hidroksinaftalen-2-karboksilata, metansulfonata i benzensulfonata.
A method according to claim 12, wherein the method further comprises the step of mounting a second coil spring, preferably a tension spring, near the second piston rod, preferably parallel hereto. 
Postupak u skladu s patentnim zahtjevom 12, naznačen time, što ovaj postupak nadalje obuhvaća fazu montiranja druge spiralne opruge, poželjno vlačne opruge, koja je u blizini drugog klipnog štapa, poželjno da je paralelna s njim.
The formulation of claim 1 wherein the rVWF comprises amino acid sequence set out in SEQ ID NO: 3; wherein the buffering agent is citrate at a concentration of about 15 mM at about pH 7.3; wherein the amino acid is glycine at a concentration of about 15 mM; wherein the stabilizing agents are trehalose at a concentration of about 10 g/L and mannitol at a concentration of about 20 g/L; and wherein the surfactant is TWEEN-80 at about 0.1 g/L. 
Formulacija prema zahtjevu 1, naznačena time da rVWF sadrži amino kiselinsku sekvencu prikazanu u SEQ ID NO:3; gdje je pufer citrat u koncentraciji u otopini od oko 15 mM na oko pH 7.3; gdje je amino kiselina glicin u koncentraciji u otopini od oko 15 mM; gdje su sredstva za stabilizaciju trehaloza u koncentraciji u otopini od oko 10 g/1 i manitol u koncentraciji od oko 20 g/l; i gdje je površinski aktivno sredstvo TWEEN-80 pri oko 0.1 g/l u otopini.
R is selected from the group consisting of 
R je odabran iz skupine koju čine
The composition for the use according to any one of claims 1 to 5, wherein said oily vehicle consists of hydrogenated polydecene. 
Pripravak za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što se navedeni uljani nosač sastoji od hidrogeniranog polidecena.
A compound of formula (I) as defined in claim 1 or 2 and/or physiologically acceptable salts and/or hydrates and/or solvates thereof for use in a method of treating and/or preventing a disease selected from psychiatric disorders, neurological disorders, chronic and acute pain, neuromuscular dysfunctions of the lower urinary tract, gastrointestinal reflux disease, irritable bowel syndrome, substance abuse and withdrawal. 
Spoj formule (I) prema zahtjevima 1 ili 2 i/ili njegove fiziološki prihvatljive soli i/ili hidrati i/ili solvati, naznačen time, da se upotrebljava u postupku prevencije i/ili liječenja poremećaja odabranog od sljedećih: psihijatrijski poremećaji, neurološki poremećaji, kronični 1 akutni bolovi, neuromuskularna disfunkcija donjeg urinarnog trakta, gastrointestinalna refluksna bolest, sindrom osjetljivih crijeva, zlouporaba loših tvari i odvikavanje od uzimanja loših tvari.
(0-1') providing a compound of formula VI' 
(0-1) pripravljanje spoja formule VI' o
wherein (n) is an integer from 2 to about 4000, and unreacted di(1-benzotriazolyl) carbonate; 
HR P20150247 T1 pri čemu (n) je cijeli broj od 2 do 4000, i neizreagirani p-nitrofenil kloroformat;
The crystalline form III obtained from dichloromethane/n-hexane has a DRX as shown in Fig. 7 and/or a DSC as shown in Fig. 8 and/or an IR as shown in Fig. 9 . 
Korteksolon-17a-propionat u kristalnom obliku II u skladu s patentnim zahtjevom 15, naznačen time što ima DRX spektar, kao što je prikazan na Slici 7 1 DSC spektar, kao što je prikazan na Slici 8, te što ima IR spektar, kao što je prikazan na Slici 9.
In step (d) the clopidogrel hydrogen sulfate of form I is recovered. 
(d) klopidogrel-vodik-sulfat se obnavlja u oblik I.
The rate of application of the Sulfonamides is usually 0.1 to 200 g/ha, as a rule 1 to 100 g/ha, preferably 2 to 100 g/ha, of active substance (a.s.). 
Stopa primjene imazamoksa je obično 0.1 do 200 g/ha, kao pravilo, 1 do 100 g/ha, poželjno 2 do 100 g/ha aktivne supstance.
The crude product was dissolved in CH2Cl2 (250 ml) and the solution was filtered through Celite(30 ml). 
Sirovi produkt je otopljen u CH2Ck (250 mL) i otopina je filtrirana kroz Celit (30 mL).
Method according to claim 1, characterized in that said scavenger is an ion exchange scavenger. 
Postupak prema zahtjevu 1, naznačen time što navedeni pročišćivač jest ionsko izmjenjivački pročišćivač.
The method of claim 1, the compound represented by a structure of Formula 5 or stereoisomer thereof or pharmaceutically acceptable salt thereof 
RH I s u NE s k s 1, tvar sadrži strukturu Formule 5 ili njen stereoizomer ili njenu farmaceutski
eye diseases, which coincide with inflammatory, allergic and/or proliferative processes, 
(x) bolesti oka, koje se poklapaju s upalnim, alergijskim i/ili proliferativnim procesima,
Preferably, the volume ratio between said stable second phase and said metastable first phase of said zirconia particles is at least 1.005, such as at least 1.01 or even at least 1.02 or at least 1.03. 
Preferirano, volumni omjer između rečene stabilne druge faze i rečene metastabilne prve faze rečenih čestica cirkonijeva oksida je najmanje 1.005, kao stoje najmanje 1.01 ili čak najmanje 1.02 ili najmanje 1.03.
A ceramic article in the form of a sanitary, culinary or laboratory article, comprising a ceramic base body and also a fired glaze applied on said base body, the fired glaze comprising SiO2 at 45-55 mass %, Al2O3 at 6-12 mass %, ZnO at 15-35 mass %, and additionally PbO at 0.1-15 mass % and/or CuO at 0.025-2 mass % and/or Bi2O3 at 0.25-7 mass %, wherein the ZnO combined with the PbO and/or CuO and/or Bi2O3 are in amounts that provide enhanced antimicrobial characteristics compared to antimicrobial characteristics of ZnO alone. 
HR P20190945 T1 PATENTNI ZAHTJEVI ze Keramički predmet u obliku sanitarnog, kuhinjskog ili laboratorijskog predmeta, koji se sastoji od keramičkog osnovnog tijela i također pečene glazure nanesene na osnovno tijelo, te pečena glazura sadrži SiO> u količini 45-55 masenih %, AbOz; u količini 6-12 masenih %, ZnO u količini 15-35 masenih %, te dodatno PbO u količini 0.1-15 masenih % i/ili CuO u količini 0.025-2 masenih % i/ili Bi203 u količini 0.25-7 masenih %.
a triangle such that either the X-altitude or the X-median intercepts the central axis (Z) of the nozzle through bore at the through bore centre (46); 
trokut kod kojeg ili visina X ili medijan X koji siječe središnju os (Z) provrta mlaznice u središtu provrta (46);
The process of claim 8 wherein the organic solvent and the second organic solvent are the same and are both alcohols or wherein the organic solvent and the second organic solvent are isopropanol. 
Postupak prema patentnom zahtjevu 8, naznačen time, da su organsko otapalo i drugo organsko otapalo isti i oba su alkoholi, ili pri čemu su organsko otapalo i drugo organsko otapalo izopropanol.
The present invention relates to a therapeutic hosiery item and to a method for manufacturing the same with a circular hosiery knitting machine. 
Tehničko područje Predloženi izum se odnosi na terapeutsku čarapu i na postupak za njezinu proizvodnju kružnim strojem za pletenje čarapa.
A blended wax according to any preceding claim further comprising 1-16% micro-wax, 0-5% natural and/or synthetic waxes, 20-50% resinous material, 0-5% polymers, 0-30% fillers by weight of the total blended wax. 
Miješani vosak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što dodatno sadrži 1-16 % mikrovoska, 0-5 % prirodnih i/ili sintetskih voskova, 20-50 % smolastog materijala, 0-5 % polimera, 0-30 % punila, težinski, od ukupnog miješanog voska.
A compound of formula (IIa) or (IIb) for use in a method of treatment as described in claim 8, wherein the compound is selected from the group consisting of: ID 
Spoj, ili njegova sol ili solvat, ili farmaceutski pripravak, za uporabu u liječenju naznačen time, da se spoj bira iz skupine koja se sastoji od:
The effectiveness of a compound as a GnRH receptor antagonist may be determined by various assay techniques. 
Djelotvornost spoja kao antagonista receptora GnRH može se odrediti različitim tehnike ispitivanja.
during the process air treatment step, the process air taken from the compressed air source (30) is first subjected to a pre-cooling sub-step and then to the cooling sub-step; during the pre-cooling sub-step the process air is conveyed and made to pass in a first heat exchanger (50), in which the process air transfers heat to a heat exchange liquid cooled by a refrigerating section (5), the heat exchange liquid recirculating in a respective closed circuit comprising the first heat exchanger (50). 
- < tijekom koraka obrade zraka za postupak, zrak za postupak uzet iz izvora komprimiranog zraka (30) prvo je podvrgnut pod-koraku prethodnog-hlađenja, a zatim pod-koraku hlađenja; tijekom pod-koraka prethodnog- hlađenja zrak za postupak se transportira i provodi kroz prvi izmjenjivač topline (50), u kojem zrak za postupak prenosi toplinu na tekućinu za izmjenu topline koja je ohlađena pomoću rashladnog bloka (5), a tekućina za izmjenu topline je u optoku u odgovarajućem zatvorenom krugu koji sadrži prvi izmjenjivač topline (50).
In some cases, nuclear magnetic resonance experiments were also carried out using the pulse sequences APT (Attached Proton Test), HETCOR (Heteronuclear Chemical Shift Correlation) or COSY (Correlated Spectroscopy) as an aid to assignment. 
U nekim slučajevima, pokusi magnetske rezonancije su provedeni također i upotrebom pulsnih sekvenci APT (Attached Proton Test), HETCOR (korelacija heteronuklearnog kemijskog pomaka) ili COSY (korelirana spektroskopija) kao pomoći za ocjenjivanje.
2 shows a view in perspective of a component part (antenna) of the FIG. 
prikazuje pcrspcktivni izgled dijela komponente (antene) balize iz Slikc 1;
The process of claim 1 wherein the chondroitin sodium salt of step a) is obtained starting either from the capsular polysaccharide K4 produced by a culture broth of E. Coli strain O5:K4:H4, or from the polysaccharide produced by a culture broth of E. Coli strain DSM23644. 
Postupak iz patentnog zahtjeva 1 naznačeno time da je natrijeva sol kondroitina iz koraka a) dobivena polazeći ili iz kapsularnog polisaharida K4 dobivenog od kulture £. coli u bujonu soja O5:K4:H4, ili iz polisaharida dobivenog od kulture £. coli u bujonu soja DSM23644.
In a preferred embodiment, step (d) provides a method to prepare a compound of formula (3), preferably wherein R1 and R2 are H and R3 is ethyl, or salt thereof, in a diastereomeric ratio of (3-a) to (3-b) of at least 60:40, preferably of at least 70:30, more preferably of at least 80:20, yet more preferably of at least 90:10, most preferably of at least 99:1. 
20. Postupak prema bilo kojem od zahtjeva 17 do 19, naznačen time, da se proizvodi spoj prema formuli (3) u omjeru sljedećih dijastereomera (3-a) prema (3-b): od najmanje 60: 40, poželjno najmanje 70: 30, još poželjnije najmanje 80: 20, još bolje od najmanje 90: 10, te najbolje od najmanje 99: 1.
It should be appreciated that the R2 group attached at C-3 in Scheme 8 may be different from the R2 group that was on the sidechain that was removed in Scheme 7. 
Trebalo bi uvažiti da R, skupina koja je priključena na C-3 u shemi 8 može biti različita od R, skupine koja je bila bočni lanac koji je bio uklonjen u shemi 7.